高级检索
当前位置: 首页 > 详情页

The landscape of new drugs in extranodal NK/T-cell lymphoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing 100730, Peoples R China [2]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China [3]Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China [4]Peking Union Med Coll Hosp, Dept Breast Surg, Beijing 100032, Peoples R China [5]Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing 100730, Peoples R China [6]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing 100730, Peoples R China
出处:
ISSN:

关键词: Targeted therapy Immunotherapy Extranodal NK/T-cell lymphoma Adoptive T-cell therapy Chemotherapy resistance

摘要:
To date, much progress has been made in early-stage extranodal NK/T-cell lymphoma (ENKTCL), and risk-adapted therapy with radiotherapy (RT) alone for the low-risk group and RT combined with asparaginase-based chemotherapy (CT) for the high-risk group yields favorable outcomes. However, optimal treatment strategies have not been defined yet for advanced-stage ENKTCL. Historically, ENKTCL responded poorly to conventional anthracycline-based chemotherapy probably because of inherent multidrug resistance (MDR). The fact that ENKTCL cells lack asparagine synthetase (ASNS) activity warranted the use of L-asparaginase or pegaspargase as frontline chemotherapies. Even though, due to high mortality of the disease, approximately 50% patients failing the frontline therapy arrived at dismal clinical outcomes with a median progression-free survival (PFS) less than 8 months. As distinctive molecular and biological subgroups are increasingly discovered within the disease entity of ENKTCL, novel targeted therapies and immunotherapy are of the urgent need for those heterogeneous subgroups. In this review, we sought to summarize the preclinical and clinical results of 6 categories of promising targeted therapy and immunotherapy for the treatment of ENKTCL, including monoclonal antibodies, immune checkpoint inhibitors, small-molecular inhibitors, epigenetic therapy, immunomodulatory drugs, and adoptive T-cell therapy, and these might change the landscape of treatment for ENKTCL in the near future.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing 100730, Peoples R China [2]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China [3]Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China [*1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
共同第一作者:
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing 100730, Peoples R China [2]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China [3]Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China [*1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21434 今日访问量:0 总访问量:1221 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)